e-learning
resources
Stockholm 2007
Sunday 16.09.2007
New drugs for COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
REPAIR II:
r
etinoid treatment of
e
mphysema
p
atients on the
a
lpha-1-antitrypsin
i
nternational
r
egistry
J. Stolk, R. A. Stockley, A. Rames, O. Rutman, S. Soliman (RC Leiden, Netherlands; Birmingham, United Kingdom; Basel, Switzerland)
Source:
Annual Congress 2007 - New drugs for COPD
Session:
New drugs for COPD
Session type:
Oral Presentation
Number:
1293
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Stolk, R. A. Stockley, A. Rames, O. Rutman, S. Soliman (RC Leiden, Netherlands; Birmingham, United Kingdom; Basel, Switzerland). REPAIR II:
r
etinoid treatment of
e
mphysema
p
atients on the
a
lpha-1-antitrypsin
i
nternational
r
egistry. Eur Respir J 2007; 30: Suppl. 51, 1293
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Imaging of complicated pneumonia: what is new?
Related content which might interest you:
Functional decline over time in patients with IPF treated with pirfenidone: the PROOF registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018
PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients
Source: International Congress 2016 – IPF clinical
Year: 2016
Epidemiology and mortality of non-idiopathic pulmonary fibrosis (IPF) progressive fibrosing interstitial lung disease (PF-ILD) using the French national health insurance system (SNDS) database in France: the PROGRESS study
Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more
Year: 2020
Prospective observational study in patients with obstructive lung disease: NOVELTY design
Source: ERJ Open Res, 5 (1) 00036-2018; 10.1183/23120541.00036-2018
Year: 2019
Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Evaluation of roflumilast in COPD patients in a real-world European setting: results from the PROFILE EU study
Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies?
Year: 2017
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Source: Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020
Year: 2021
Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study
Source: Virtual Congress 2020 – Monitoring of inflammation in remodelling
Year: 2020
CompERA-XL: International, prospective registry for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Health and functional status of tiotropium/olodaterol-treated patients with COPD: results from the AERIAL® non-interventional study
Source: ERJ Open Res, 7 (3) 00004-2021; 10.1183/23120541.00004-2021
Year: 2021
Incidence of multiple progression events in patients with idiopathic pulmonary fibrosis (IPF) in the pooled CAPACITY and ASCEND trials
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Assessment of costs and outcomes of chemotherapy in an observational setting in patients with advanced NSCLC (ACTION)
Source: Eur Respir J 2004; 24: Suppl. 48, 304s
Year: 2004
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry
Source: Eur Respir J 2015; 46: 186-196
Year: 2015
TOPP: the first international registry in pediatric pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008
The national alpha-1 antitrypsin deficiency registry in Poland
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015
Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Randomised controlled trial for emphysema with a selective agonist of the ?-type retinoic acid receptor
Source: Eur Respir J 2012; 40: 306-312
Year: 2012
Pulmonary embolism in the multicentre advanced study for a thromboembolism registry (MASTER): study design and patients recruited
Source: Eur Respir J 2005; 26: Suppl. 49, 595s
Year: 2005
Protocol for the EARCO Registry: a pan-European observational study in patients with a
1
-antitrypsin deficiency
Source: ERJ Open Res, 6 (1) 00181-2019; 10.1183/23120541.00181-2019
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept